HRP970478B1 - Indazole derivatives - Google Patents

Indazole derivatives

Info

Publication number
HRP970478B1
HRP970478B1 HR970478A HRP970478A HRP970478B1 HR P970478 B1 HRP970478 B1 HR P970478B1 HR 970478 A HR970478 A HR 970478A HR P970478 A HRP970478 A HR P970478A HR P970478 B1 HRP970478 B1 HR P970478B1
Authority
HR
Croatia
Prior art keywords
indazole derivatives
indazole
derivatives
Prior art date
Application number
HR970478A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP970478A2 publication Critical patent/HRP970478A2/hr
Publication of HRP970478B1 publication Critical patent/HRP970478B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR970478A 1996-09-04 1997-09-04 Indazole derivatives HRP970478B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2544696P 1996-09-04 1996-09-04

Publications (2)

Publication Number Publication Date
HRP970478A2 HRP970478A2 (en) 1998-08-31
HRP970478B1 true HRP970478B1 (en) 2002-10-31

Family

ID=21826124

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970478A HRP970478B1 (en) 1996-09-04 1997-09-04 Indazole derivatives

Country Status (35)

Country Link
US (1) US6262040B1 (fr)
EP (1) EP0931075A1 (fr)
JP (2) JP3554337B2 (fr)
KR (1) KR100338610B1 (fr)
CN (1) CN1234031A (fr)
AP (1) AP795A (fr)
AR (1) AR008162A1 (fr)
AU (1) AU724549B2 (fr)
BG (1) BG64447B1 (fr)
BR (1) BR9712005A (fr)
CA (1) CA2264798A1 (fr)
CO (1) CO4600636A1 (fr)
DZ (1) DZ2303A1 (fr)
EA (1) EA002113B1 (fr)
GT (1) GT199700102A (fr)
HN (1) HN1997000126A (fr)
HR (1) HRP970478B1 (fr)
HU (1) HUP9903248A3 (fr)
ID (1) ID18157A (fr)
IL (1) IL128642A0 (fr)
IS (1) IS4979A (fr)
MA (1) MA26439A1 (fr)
NO (1) NO991048L (fr)
NZ (1) NZ334213A (fr)
OA (1) OA10985A (fr)
PA (1) PA8437301A1 (fr)
PE (1) PE107998A1 (fr)
PL (1) PL332187A1 (fr)
SK (1) SK27299A3 (fr)
TN (1) TNSN97148A1 (fr)
TR (1) TR199900481T2 (fr)
TW (1) TW402595B (fr)
WO (1) WO1998009961A1 (fr)
YU (1) YU11299A (fr)
ZA (1) ZA977903B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
TR200001256T2 (tr) * 1997-11-04 2000-11-21 Pfizer Products Inc. Terapötik olarak aktif bileşimler.
PL340753A1 (en) * 1997-11-04 2001-02-26 Pfizer Prod Inc Substitution of indazolic bioisoster for cathechol in therapeutically active compounds
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2715683A1 (fr) 1999-08-21 2001-03-01 Nycomed Gmbh Combinaison synergiste
WO2001047915A1 (fr) * 1999-12-23 2001-07-05 Icos Corporation Inhibiteurs de phosphodiesterase specifique d'amp cyclique
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2002094320A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
WO2002094321A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2003087333A2 (fr) * 2002-04-12 2003-10-23 Celgene Corporation Modulation de differenciation de cellule souche et de cellule progenitrice, analyses et utilisations associees
WO2003102151A2 (fr) * 2002-05-30 2003-12-11 Celgene Corporation Procedes d'utilisation d'inhibiteurs de jnk ou de mkk en vue de moduler la differenciation cellulaire et de traiter des troubles myeloproliferatifs et des syndromes myelodysplasiques
RU2354648C2 (ru) * 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
CA2492907A1 (fr) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Inhibiteurs de phosphodiesterase 4 comprenant des analogues de diphenylamine et d'aniline n-substitues
EP1569908B1 (fr) * 2002-11-19 2010-09-15 Memory Pharmaceuticals Corporation Pyridines N-Oxyde comme iNHIBITEURS DE LA PHOSPHODIESTERASE 4
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EA013248B1 (ru) 2002-12-20 2010-04-30 Пфайзер Продактс Инк. Производные пиримидина для лечения патологического роста клеток
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja) 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
WO2005111016A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
WO2005111022A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives pyrimidiques pour le traitement de la croissance de cellules anormales
JP2008505969A (ja) * 2004-07-12 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ヒストン脱アセチル化酵素の阻害剤
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
WO2006129158A2 (fr) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase de type iv
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1928866A1 (fr) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
EP2091329A4 (fr) * 2006-12-05 2011-02-23 Univ Nat Chiao Tung Composés d'indazole
PT2124944E (pt) 2007-03-14 2012-05-17 Ranbaxy Lab Ltd Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
WO2010003084A2 (fr) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiestérase 4
ES2660892T3 (es) * 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
JP2013525370A (ja) * 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
EP3323820B1 (fr) 2011-02-28 2023-05-10 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
WO2015166370A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
KR20190078646A (ko) * 2016-11-18 2019-07-04 머크 샤프 앤드 돔 코포레이션 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
US20240279828A1 (en) * 2021-05-31 2024-08-22 Genscript Usa Inc. Electrografted films for dna synthesis
TWI907890B (zh) * 2022-12-14 2025-12-11 國立成功大學 化合物及其合成方法與應用
CN116003325B (zh) * 2023-01-09 2025-04-25 南方医科大学 吲唑类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531433A (fr) * 1953-06-17
US4665397A (en) 1983-11-01 1987-05-12 Universal Photonics, Inc. Apparatus and method for a universal electronic locking system
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
JPS6250751A (ja) * 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
EP0381422B1 (fr) * 1989-02-02 1996-10-23 Yamanouchi Pharmaceutical Co. Ltd. Dérivés de tétrahydrobenzimidazole
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU695301B2 (en) * 1993-07-06 1998-08-13 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JPH09510191A (ja) 1994-02-17 1997-10-14 アメリカン・ホーム・プロダクツ・コーポレイション ホスホジエステラーゼ阻害薬としての置換ビフェニル誘導体
WO1995027692A1 (fr) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Inhibiteurs du facteur de necrose tumorale a substitution biphenyle
JPH08143525A (ja) * 1994-11-21 1996-06-04 Banyu Pharmaceut Co Ltd ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
EA002274B1 (ru) * 1996-06-25 2002-02-28 Пфайзер Инк. Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate

Also Published As

Publication number Publication date
ZA977903B (en) 1999-03-03
EA002113B1 (ru) 2001-12-24
OA10985A (en) 2001-11-01
HN1997000126A (es) 1997-12-26
JP2000502724A (ja) 2000-03-07
HRP970478A2 (en) 1998-08-31
AU3781397A (en) 1998-03-26
PE107998A1 (es) 1999-01-30
TW402595B (en) 2000-08-21
KR20000068421A (ko) 2000-11-25
AR008162A1 (es) 1999-12-09
MA26439A1 (fr) 2004-12-20
HUP9903248A2 (hu) 2000-04-28
AU724549B2 (en) 2000-09-28
NO991048L (no) 1999-05-03
AP795A (en) 1999-12-28
PA8437301A1 (es) 1999-12-27
SK27299A3 (en) 2000-10-09
US6262040B1 (en) 2001-07-17
DZ2303A1 (fr) 2002-12-28
GT199700102A (es) 1999-02-25
YU11299A (sh) 2001-07-10
BR9712005A (pt) 1999-08-24
BG64447B1 (en) 2005-02-28
IS4979A (is) 1999-02-16
TR199900481T2 (xx) 1999-06-21
HUP9903248A3 (en) 2000-07-28
NO991048D0 (no) 1999-03-03
EP0931075A1 (fr) 1999-07-28
IL128642A0 (en) 2000-01-31
WO1998009961A1 (fr) 1998-03-12
BG103195A (en) 1999-09-30
ID18157A (id) 1998-03-05
JP2004217668A (ja) 2004-08-05
EA199900183A1 (ru) 1999-08-26
NZ334213A (en) 2000-08-25
PL332187A1 (en) 1999-08-30
JP3554337B2 (ja) 2004-08-18
AP9701080A0 (en) 1997-10-31
TNSN97148A1 (fr) 2005-03-15
CO4600636A1 (es) 1998-05-08
CN1234031A (zh) 1999-11-03
CA2264798A1 (fr) 1998-03-12
KR100338610B1 (ko) 2002-05-27

Similar Documents

Publication Publication Date Title
ZA977903B (en) Indazole derivatives
AP9700954A0 (en) 6-ohenylpyridyl-2-amine derivatives
AP9700975A0 (en) Substituted indazole derivatives and related compounds
HU9700358D0 (en) New oxazolidinon derivatives
AP9701156A0 (en) 6-phenylpyridyl-2-amine derivatives
IL125379A (en) 19-nor-pregnene derivatives
ZA974053B (en) Alkylaminobenzothiazole and -benzoxazole derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
HU9701479D0 (en) N-benzylazolium derivatives
PL334558A1 (en) Cephalosporinic derivatives
GB9604996D0 (en) Benzodiazonine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
GB9600063D0 (en) Guaridine derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
IL125974A0 (en) 2-thioxotetrahydropyrimidin-4-one derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
GB9603581D0 (en) Amino-benzothiazole derivatives
ZA971502B (en) Pyrazol-4-yl-hetaroyl derivatives
IL145863A (en) Benzothiophenecarboxamide derivatives
GB9610888D0 (en) Aralkoxy-morphinan derivatives
ZA972808B (en) aminodihydropyridine derivatives
ZA97172B (en) Heterocycle-condensed morphinoid derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20020904

Year of fee payment: 6

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20030905